Combined Immunotherapy and Conventional Chemotherapy in Cancer Patients
Publish place: Third National Festival and International Congress of Rehabilitation Stem Cells and Medical Stems and Technologies
Publish Year: 1397
نوع سند: مقاله کنفرانسی
زبان: English
View: 433
نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد
- Certificate
- من نویسنده این مقاله هستم
این Paper در بخشهای موضوعی زیر دسته بندی شده است:
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
NSCMRMED03_088
تاریخ نمایه سازی: 30 دی 1397
Abstract:
Despite promising success in immunotherapy of cancer patients, aconsiderable part of these patients does not reach to optimum responseto these agents such as PD-1 and PD-L1 inhibitors. Recent interest isto achieve the additive efficacy of immunotherapy in combinationwith conventional chemotherapy agents. The schedule and dosage ofchemotherapy agents like metronomic treatment can play as a gamechanger in this strategy. This integration of immunotherapy with standardcancer therapy can promote immunogenic cell death with a variousmechanism such as modulate the immune phenotype of residual tumor cells, minimize of the negative impact of tumor burden and up-regulationthe expression of tumor antigen.
Keywords:
Authors
Alireza Rezvani
Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran